Subscribe To
ZVRA / Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
ZVRA News
By GlobeNewsWire
October 31, 2023
Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET
CELEBRATION, Fla., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics com more_horizontal
By GlobeNewsWire
October 5, 2023
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs more_horizontal
By Seeking Alpha
September 5, 2023
Zevra's Rare Find: Unearthing Value In Niche Rare Diseases The Market Overlooks
Zevra's acquisition of Acer Therapeutics adds significant value to its rare disease-focused strategy. Acer's newly launched product, Olpruva, aligns w more_horizontal
By Zacks Investment Research
September 4, 2023
How Much Upside is Left in Zevra Therapeutics (ZVRA)? Wall Street Analysts Think 248.51%
The consensus price target hints at a 248.5% upside potential for Zevra Therapeutics (ZVRA). While empirical research shows that this sought-after met more_horizontal
By Zacks Investment Research
May 15, 2023
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to l more_horizontal
By GlobeNewsWire
May 9, 2023
Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023
CELEBRATION, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare more_horizontal
By Seeking Alpha
March 10, 2023
Zevra Therapeutics, Inc. (ZVRA) Q4 2022 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Nichol Ochsner - Vice President more_horizontal
By GlobeNewsWire
March 6, 2023
Zevra Therapeutics to Present at 35th Annual Roth Conference
CELEBRATION, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPhar more_horizontal